-
Novo raises outlook amid Wegovy pill succes
Novo's obesity drugs keeps driving sales, and the launch of the Wegovy pill makes Novo raise its full-year outlook.
-
UK ends uncertainty over CE marking for medical devices
Medical device manufacturers will be spared duplicate certification processes to access the British market. The UK government has decided to recognise CE marking indefinitely, a move welcomed by industry.
-
GSK to cut 1,200 jobs in Belgium
More than 1,200 jobs at UK pharma giant GSK are at risk in Belgium as part of a major cost-cutting drive.
-
Camurus takes next step with Oczyesa – wins Canadian approval
Swedish pharmaceutical company Camurus has secured another marketing approval for its acromegaly treatment. Canada has now approved Oczyesa XR, which patients can inject themselves once a month.
-
How GLP-1 drugs are changing what we buy at the supermarket
In both Sweden and Denmark, grocery industry organisations are predicting billion-krona sales losses as the use of weight-loss drugs increases. So far, however, major supermarket chains say they have seen little sign of an impact.
-
Natural Cycles sharpens Nordic focus with new regional chief
After nearly a decade at Natural Cycles, Sofie Askervall has stepped into the newly created role of Head of Nordics. “Right now, we are looking closely at Norway,” she says.
-
AstraZeneca opens $1bn R&D centre in US
AstraZeneca has now opened its new research and development centre in Cambridge, Massachusetts – an investment of nearly 1 billion dollars.
-
Study finds key gut bacterium undetectable in one in three Swedish infants
One in three Swedish infants have no detectable levels of a bacterium that helps support the developing immune system, according to a new Swedish study. The figure is notably high compared with similar studies from the UK and US.
-
Danish BioInnovation Institute sets sights on Europe
Great science is not enough to build successful companies. As BioInnovation Institute looks beyond Denmark, CEO Jens Nielsen sees access to the right capital as one of the biggest obstacles facing Europe’s research-based startups.
-
Sweden takes half of Nordic spots among world’s top healthtech companies
Ten Nordic companies have made it onto TIME’s list of the World’s Top HealthTech Companies 2026, and half of them are Swedish. Denmark accounts for three, while Norway and Iceland each have one company on the list.
-
Tandem Health raises $100m to expand in Europe
Swedish AI company Tandem Health has raised $100m. The funding will be used to strengthen the company’s position in Europe.
-
GSK’s potential blockbuster makes Swedish comeback
Following the withdrawal of its marketing authorisation and an earlier recommendation against its use, GSK’s Blenrep is making a comeback in Sweden. The Swedish New Therapies Council (NT-rådet) now recommends the drug from the second line of treatment for multiple myeloma.
-
BioArctic chair: “First, you need to know where you’re going”
He has been a researcher, doctor, investor and business leader. But when Eugen Steiner explains BioArctic’s success, he keeps coming back to the same thing: its vision. Speaking to Life Science Focus, he discusses CEO recruitment, the founders’ determination and why Sweden risks falling behind in clinical research.
-
Sanofi Sweden: ”We will work for more clinical trials”
Sanofi Sweden may represent only a modest share of the global Sanofi group, which employs nearly 80,000 people, but it still makes a significant research impact. Sweden Country Manager Daniel Sandgren hopes that will remain the case – yet he also sees clouds on the horizon.“Sweden risks losing its strong position in clinical trials”, he says in an interview.
-
Saniona’s neurology collaboration advances as AstronauTx Exercises acquisition option
UK‑based AstronauTx exercises an option to acquire a drug program in neurological diseases from Danish‑Swedish Saniona.
-
Hansa Biopharma secures billion deal: “Profitability within reach”
Lund-based Hansa Biopharma is raising more than SEK 1bn through a new licensing agreement for its in-house developed transplant drug imlifidase.
-
Massläcka från känd biobank – data från halv miljon ute till försäljning
Medicinska uppgifter från omkring 500 000 britter har lagts ut till försäljning på en kinesisk e-handelsplattform. Datan kommer från forskningsdatabasen UK Biobank – en av världens största befolkningskohorter.
-
Multicancer test failed to meet its goal – shares plunged
A blood test designed to detect multiple types of cancer failed to meet its primary endpoint in a large UK study. The company behind the test saw its market value cut in half.
-
List: The companies behind 38 new pharmaceutical substances in the EU
In 2025, the European Medicines Agency (EMA) recommended 104 medicines for approval. Of these, 38 contained a new active substance that had never before been authorised in the EU. Life Science Sweden has mapped the companies and countries behind the new substances.
-
“Access to capital increases when there’s an exit”
It remains a tough environment for biotech companies seeking financing – but there is good reason to hope for improvement ahead. That’s the view of Okee Williams, Corporate Adviser at Redeye.
-
Sarah Lidé: ”När AI lär sig förutse – inte bara nästa ord, utan nästa sjukdom”
I takt med att generativ AI mognar öppnas nya möjligheter att omforma hur vi förstår och förebygger sjukdomar, skriver Sarah Lidé i en krönika.
-
Babypuderskandalen når Europa – första stämningen mot J&J i Storbritannien
De enorma skadeståndsprocesserna mot Johnson & Johnson, vars talkpuder påstås ha orsakat cancer, har nu även nått Storbritannien.
-
Phase III win for Hansa Biopharma: “We Are Thrilled”
Swedish biotech Hansa Biopharma’s transplant drug imlifidase has met the primary efficacy endpoint in a registration-enabling Phase III study in the United States.
-
Astra Zeneca pauses multi-million investment in the UK
Astra Zeneca has paused a planned investment worth $270 million. It is the latest pharmaceutical company to pull back on its commitments in the UK.
Get access to all content on Life Science Focus
No commitment or card information required
Already a subscriber? Log In
Applies to personal subscription only.
Contact us for a enterprise solution.
Advertisement
Advertisement
Advertisement
Advertisement
BREAKING